## CLAIMS

What is claimed:

1. A capsule comprising cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in an amount that is 30-40% of the capsule by weight, an excipient in an amount that is 50-60% of the capsule by weight, and tocophersolan in an amount that is 5-15% of the capsule by weight.

2. The capsule of claim 1, wherein cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide is present in about 37% by weight.

3. The capsule of claim 1, wherein the excipient is hydroxypropyl methylcellulose.

4. The capsule of claim 3, wherein the hydroxypropyl methylcellulose is present in an amount of about 53% by weight.

5. The capsule of claim 1, wherein the tocophersolan is present in an amount of about 10% by weight.

6. A capsule comprising 60-70% cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof by weight, 20-30% of an excipient by weight, and 5-15% of tocophersolan by weight.

7. The capsule of claim 6, wherein the excipient is hydroxypropyl methylcellulose.

8. The capsule of claim 6, wherein the excipient is polyvinylacetate phthalate polymer.

9. The capsule of claim 6, wherein the excipient is vinylpyrrolidone-vinyl acetate copolymer.

10. The capsule of claim 6, wherein the capsule comprises about 65% cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide by weight.

11. The capsule of claim 6, wherein the capsule comprises about 25% cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide by weight.

12. The capsule of claim 6, wherein the capsule comprises about 10% tocophersolan by weight.

13. A capsule comprising 45-55% cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof by weight, 35-45% of an excipient by weight, and 5-15% of tocophersolan by weight.

14. The capsule of claim 13, wherein the excipient is hydroxypropyl methylcellulose.

15. The capsule of claim 13, wherein the excipient is polyvinylacetate phthalate polymer.

16. The capsule of claim 13, wherein the excipient is vinylpyrrolidone-vinyl acetate copolymer.

17. The capsule of claim 13, wherein the capsule comprises about 50% cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide by weight.

18. The capsule of claim 13, wherein the capsule comprises about 40% excipient by weight.

19. The capsule of claim 13, wherein the capsule comprises about 10% tocophersolan by weight.

20. A capsule comprising a citrate salt of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-

(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide in an amount that is 0.5-20% of the capsule weight, and sodium lauryl sulfate.

21. The capsule of claim 20, wherein the capsule comprises 0.5-3% of a citrate salt of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide by weight and 0.5-3% sodium lauryl sulfate by weight.

22. The capsule of claim 21, wherein the capsule comprises about 1.79% of a citrate salt of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide by weight and about 1.0% sodium lauryl sulfate by weight.

23. The capsule of claim 21, wherein the capsule further comprises 10-30% microcrystalline cellulose by weight, 55-75% mannitol by weight, 2-8% fumaric acid by weight, 1-7% crospovidone by weight, 0.2-1% fumed silica by weight, and 0.5-3% magnesium stearate by weight.

24. The capsule of claim 23, wherein the capsule comprises about 1.79% of the citrate salt of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide by weight.

25. The capsule of claim 23, wherein the capsule comprises about 21.65% microcrystalline cellulose by weight.

26. The capsule of claim 23, wherein the capsule comprises about 64.96% mannitol by weight.

27. The capsule of claim 23, wherein the capsule comprises about 1.0% sodium lauryl sulfate by weight.

28. The capsule of claim 23, wherein the capsule comprises about 5.0% fumaric acid by weight.

29. The capsule of claim 23, wherein the capsule comprises about 4.0% crospovidone by weight.

30. The capsule of claim 23, wherein the capsule comprises about 0.6% fumed silica by weight.

31. The capsule of claim 23, wherein the capsule comprises about 1.0% magnesium stearate by weight.

32. The capsule of claim 20, wherein the capsule comprises 2-12% of a citrate salt of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide by weight and 0.5-3% sodium lauryl sulfate by weight.

33. The capsule of claim 32, wherein the capsule comprises about 6.70% of a citrate salt of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide by weight and about 1.0% sodium lauryl sulfate by weight.

34. The capsule of claim 32, wherein the capsule further comprises 10-30% microcrystalline cellulose by weight, 50-70% mannitol by weight, 2-8% fumaric acid by weight, 1-7% crospovidone by weight, 0.2-1% fumed silica by weight, and 0.5-3% magnesium stearate by weight.

35. The capsule of claim 34, wherein the capsule comprises about 6.70% of the citrate salt of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide by weight.

36. The capsule of claim 34, wherein the capsule comprises about 20.42% microcrystalline cellulose by weight.

37. The capsule of claim 34, wherein the capsule comprises about 61.28% mannitol by weight.

38. The capsule of claim 34, wherein the capsule comprises about 1.0% sodium lauryl sulfate by weight.

39. The capsule of claim 34, wherein the capsule comprises about 5.0% fumaric acid by weight.

40. The capsule of claim 34, wherein the capsule comprises about 4.0% crospovidone by weight.

41. The capsule of claim 34, wherein the capsule comprises about 0.6% fumed silica by weight.

42. The capsule of claim 34, wherein the capsule comprises about 1.0% magnesium stearate by weight.

43. The capsule of claim 20, wherein the capsule comprises 5-20% of a citrate salt of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide by weight and 0.5-3% sodium lauryl sulfate by weight.

44. The capsule of claim 43, wherein the capsule comprises about 10.72% of a citrate salt of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide by weight and about 1.0% sodium lauryl sulfate by weight.

45. The capsule of claim 43, wherein the capsule further comprises 10-30% microcrystalline cellulose by weight, 50-70% mannitol by weight, 2-8% fumaric acid by weight, 1-7% crospovidone by weight, 0.2-1% fumed silica by weight, and 0.5-3% magnesium stearate by weight.

46. The capsule of claim 45, wherein the capsule comprises about 10.72% of the citrate salt of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide by weight.

47. The capsule of claim 45, wherein the capsule comprises about 19.41% microcrystalline cellulose by weight.

48. The capsule of claim 45, wherein the capsule comprises about 58.27% mannitol by weight.

49. The capsule of claim 45, wherein the capsule comprises about 1.0% sodium lauryl sulfate by weight.

50. The capsule of claim 45, wherein the capsule comprises about 5.0% fumaric acid by weight.

51. The capsule of claim 45, wherein the capsule comprises about 4.0% crospovidone by weight.

52. The capsule of claim 45, wherein the capsule comprises about 0.6% fumed silica by weight.

53. The capsule of claim 45, wherein the capsule comprises about 1.0% magnesium stearate by weight.

54. A tablet comprising 15-25% of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide or an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co crystal, clathrate, or polymorph thereof by weight, 32-43% of microcrystalline cellulose by weight, 32-43% of mannitol by weight, 2-6% of croscarmellose sodium by weight, 0.3-0.7% of fumed silica by weight, and 0.5-1.5% magnesium stearate by weight.

55. The tablet of claim 54, wherein the tablet comprises about 20% of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide or a isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co crystal, clathrate, or polymorph thereof by weight.

56. The tablet of claim 54, wherein the tablet comprises about 37.25% of microcrystalline cellulose by weight.

57. The tablet of claim 54, wherein the tablet comprises about 37.25% of mannitol by weight.

58. The tablet of claim 54, wherein the tablet comprises about 4% of croscarmellose sodium by weight.

59. The tablet of claim 54, wherein the tablet comprises about 1% magnesium stearate by

weight.

60. The tablet of claim 54, wherein the total weight of the tablet is about 250 mg.

61. The tablet of claim 54, wherein the salt of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide is the HCl salt of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide.

62. The tablet of claim 54, wherein the salt of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide is the citrate salt of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H- -purin-9-yl]-1-methylcyclohexane-1-carboxamide.